Shenzhen Hengrui Medicine

Shenzhen Hengrui Medicine is a prominent subsidiary and research and development hub of Jiangsu Hengrui Pharmaceuticals, one of China's largest and most innovative pharmaceutical enterprises. Based in Shenzhen, the company focuses on the discovery and early-stage development of novel therapeutics, particularly small molecules and biologics targeting oncology, metabolic diseases, and autoimmune disorders. It leverages advanced technology platforms, including antibody-drug conjugates (ADCs) and PROTACs, to fuel a deep pipeline of clinical candidates. As an integral part of the Hengrui group, the Shenzhen entity benefits from a globalized R&D network and extensive manufacturing capabilities. The company is dedicated to addressing unmet medical needs through the development of high-quality, innovative medicines for patients worldwide.